Evidence map›Paper›PMID 37632460›Full record

ReviewAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2023

Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes.

Emily Ashjian, Megan Clarke, Kristen Pogue

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Effect of pharmacist interventions in chronic kidney disease: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Emily AshjianPharmacy Innovations & Partnerships, Michigan Medicine, Ann Arbor, MI.
Megan ClarkeDepartment of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
Kristen PogueDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.
Michigan Medicine · USUniversity of Michigan–Ann Arbor · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis review provides an overview of the management of chronic kidney disease (CKD) associated with type 2 diabetes (T2D), how the novel treatment class of nonsteroidal mineralocorticoid receptor antagonists (MRAs) fits within the treatment landscape, and how pharmacists can contribute to the multidisciplinary care of patients with CKD associated with T2D. SUMMARY: Optimizing pharmacotherapy for patients with CKD associated with T2D is critical to prevent or slow progression to end-stage kidney disease and reduce the incidence of cardiovascular events. However, many patients with CKD receive suboptimal treatment, in part because of the high complexity of care required, a lack of disease recognition among providers and patients, and a failure to utilize new kidney-protective therapies. Finerenone is the first nonsteroidal, selective MRA to be approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of adult patients with CKD associated with T2D. Clinical trials have demonstrated that finerenone significantly reduces the risk of cardiorenal disease progression vs placebo and has a reduced risk of hyperkalemia compared to traditional steroidal MRAs. Initiation of finerenone should follow evaluation of baseline estimated glomerular filtration rate and serum potassium levels. Consideration of potential drug-drug interactions, follow-up monitoring of potassium levels, and coordination of changes in pharmacotherapy across the patient care team are also important.

conclusionFinerenone is a valuable addition to the treatment landscape for CKD associated with T2D. Through their expertise in -medication -management, transitions of care, and patient education, clinical pharmacists are well positioned to ensure patients receive safe and effective -treatment.

Indexed as

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicAdultHumansMineralocorticoid Receptor AntagonistsNaphthyridinesPotassiumfinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesPotassiumcardiologychronic kidney diseaseclinical pharmacistdiabetesfinerenonepharmacotherapy

Identifiers

PMID37632460
PMCPMC10664185
OpenAlexW4386196902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.